Shanghai Medicilon Inc.

On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources. The "2024 Top 100 Future Healthcare" list was jointly launched by vbdata.cn, VB100, and VCBeat Research, aiming to select truly representative Chinese innovative medical practitioners who embody the future of healthcare and drive the innovative transformation process in the health and medical industry. This selection process, with a strict and fair evaluation mechanism, combines multiple stages including independent company applications, professional evaluations, cross-evaluations by supporting organizations, and final review by an expert committee. It focuses on the growth and annual performance of candidate companies across 17 secondary in...

  Recently, the Shanghai Science and Technology Commission officially issued the "Notice on the Announcement of the List of 2023 Shanghai Science and Technology Little Giants (Including Cultivation) Enterprises".   Medicilon Preclinical Research (Shanghai) LLC (MPR), a subsidiary of Medicilon , was recognized as one of the 2023 Shanghai Science and Technology Little Giants Company.  This is the second time Medicilon has received this honorary title. About Shanghai Science and Technology Little Giant The Shanghai Science and Technology Little Giant Project is jointly promoted by the Shanghai Science and Technology Commission, the Municipal Economic and Information Technology Commission, and the Municipal Finance Bureau.  It aims to deeply implement the innovation-driven development strategy, accelerate the construction of a technological innovation center with global influence, and create a large number of small technological giant enterprises with competitive advanta...

  On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).  This marks another substantial step forward in the research and development of the company's second innovative drug. Shanghai Medicilon Inc. (Medicilon), as a partner of Shijiazhuang No.4 Pharmaceutical, provided preclinical research services such as pharmacokinetics and safety evaluation for the development of SYN045 tablets, helping to successfully obtain approval. SYN045 is a Class I new drug independently developed by Shijiazhuang No.4 Pharmaceutical.  SYN045 is a selective long-acting PGI2 receptor agonist and is intended to be used for pulmonary arterial hypertension.  Preclinical studies have shown that SYN045 has good target selectivity, compound activity, and safety. Currently, Medicilon's preclinical research service platform has...

  Medicilon, the pioneer integrated pharmaceutical R&D preclinical services that offers   chemistry ,   DMPK/PD ,   CMC ,   toxicology   (GLP and non-GLP, we have 2000+ monkeys are available in house),   biology services   to pharmaceutical and biotech companies around the world. Since 2009, Medicilon’s preclinical experimental base has established research processes and quality systems that conform to international standards. It has successively passed AAALAC, GLP, NMPA, FDA, TGA, EMEA, etc., providing global pharmaceutical companies and research institutions with comprehensive preclinical pharmaceutical research and professional development services. The Medicilon Preclinical R&D Unit is composed of experienced experts and international advanced technology platforms to support clients’ projects and promote the new drug industry. The joining of Dr. Zhang Haizhou will further strengthen Medicilon's strength and competitiveness in preclinic...

  On July 25, 2023, Fosun Health Capital established by Fosun Pharma（stock code:600196.SH), reached a strategic partnership with Medicilon（stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) ( referred to as "StarMab Biology"，jointly invested by the innovation drug research fund of Fosun Group and Yaopharma) and Medicilon entered into a strategic cooperation for innovative drug IND research and application services. This strategic partnership indicates a significant step forward in the cooperation between Fosun Health Capital and Medicilon, with milestone for both parties' development. Cui Zhiping, Co-CEO and General Manager of Fosun Health Capital, Chen Chunlin, Founder and CEO of Medicilon, along with members from both sides attended the signing ceremony together and witnessed the contract. According to the strategic cooperation agreement, Medicilon will leverage its international perspective and rich experience in R&D to provide innovative drug enterprises i...

  On July 14, the IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license and agreed to carry out phase I clinical trials. The indication is ulcerative colitis. Shanghai Medicilon Inc, as a strategic partner of Biotime Biotechnology, provided  preclinical R&D services  from  target  to  IND declaration  for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency. BIOT-001 is an innovative small-molecule drug independently developed by Biotime Biotechnology with global intellectual property rights.  BIOT-001 is an orally active receptor agonist targeting S1P1.  Preclinical studies have shown that BIOT-001 can selectively bind to S1P receptor subtype 1 (S1P1) with high affinity, thereby inducing the isolation of peripheral blood lymphocytes, reducing the migration of activated circulating lymphocytes to...

  On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.  Dr. Chunlin Chen, the founder and CEO of Medicilon, and others gave a warm reception.  The two parties conducted in-depth exchanges and discussions on technological entrepreneurship, enterprise management, and industry development trends. In order to experience the development process of Medicilon, Dr. Chunlin Chen led the scientific and technological entrepreneurs to visit the Medicilon cultural wall.   Dr. Chen introduced Medicilon has adhered to scientific and technological innovation since its establishment 19 years ago, benchmarked against international frontier fields, increased investment in research and development, and overcome key core te...

  Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration.  The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy. Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy.  Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration.  Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services. Medic...

  Recently, CGeneTech (Suzhou) Co., Ltd. (CGeneTech) submitted the DPP-4 inhibitor Sitagliptin, for the treatment of type 2 diabetes, to the National Medical Products Administration (NMPA) for approval. Shanghai Medicilon Inc. (Medicilon), as a partner of CGeneTech, provided Sitagliptin with comprehensive  preclinical research services  in compliance with GLP regulations, including  pharmacodynamic research ,  pharmacokinetic research  and  safety evaluation , as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D. Medicilon Preclinical Research Platform Help drug research and development faster, better and cost-efficient Efficiency comes from collaboration, and success comes from experience.  Medicilon, as a one-stop comprehensive preclinical research and development service CRO for biopharmaceutical, has been continuously improving the scientific and technological innovation for 19 years, providing customize...

  Medicilon provide   preclinical animal studies   for clients. Animal   preclinical studies   of drug efficacy are an important resource for designing and performing clinical trials. They provide evidence of a drug’s potential clinical utility, inform the design of trials and establish the ethical basis for testing drugs in human. Several recent studies suggest that many preclinical investigations are withheld from publication. Such non-reporting likely reflects that private drug developers have little incentive to publish preclinical studies. However, it potentially deprives stakeholders of complete evidence for making risk/benefit judgments and frustrates the search for explanations when drugs fail to recapitulate the promise shown in animals. Preclinical Trial  – A laboratory test of a new drug or a new medical device, usually done on animal subjects, to see if the hoped-for treatment really works and if it is safe to test on humans. Two types of precli...

  Preclinical Drug Development Process Drug development  is time consuming and costly which contains  preclinical , clinical and after-market. In principle, if all the processes are straight-forward, a drug can be developed in a seven year period. In practice,  drug development  takes in excess of twelve years. Procedures are tightly regulated both for safety and to ensure drugs are effective. Of the many compounds studied with the potential to become a medicine, most are eliminated during the initial research phases. Clinical trials follow extensive research using in vitro and animal studies. Even so, many drugs are withdrawn or fail, never becoming approved as medicines. Common reasons include side-effects, the drug proving less effective than hoped or lacking financial viability. Preclinical Drug Development Process In  drug preclinical development , also named  preclinical studies  and nonclinical studies, is a stage of research that begi...